MARKET

ELVN

ELVN

Enliven Therapeutics Inc
NASDAQ
44.75
-0.42
-0.93%
After Hours: 44.75 0 0.00% 19:30 09/25 EDT
OPEN
45.54
PREV CLOSE
45.17
HIGH
45.77
LOW
44.18
VOLUME
963.79K
TURNOVER
--
52 WEEK HIGH
62.32
52 WEEK LOW
14.79
MARKET CAP
3.28B
P/E (TTM)
-26.8285
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELVN last week (0914-0918)?
Weekly Report · 5d ago
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:10
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
Weekly Report: what happened at ELVN last week (0907-0911)?
Weekly Report · 09/14 10:27
Weekly Report: what happened at ELVN last week (0831-0904)?
Weekly Report · 09/07 10:20
Enliven Therapeutics (ELVN) As ENABLE Data Return Puts Its 4.8x P B In Focus
Simply Wall St · 09/03 14:22
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
Seeking Alpha · 09/03 13:48
Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Benzinga · 09/01 07:57
More
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.

Webull offers Enliven Therapeutics Inc stock information, including NASDAQ: ELVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELVN stock methods without spending real money on the virtual paper trading platform.